INVESTOR PRESENTATION

Disclaimer

This Investor Presentation has been prepared by VOS HEALTHCARE LLC, USA . For investors, solely for informational purposes.

The information contained herein has been prepared to assist prospective investors in making their own evaluation of the Company and does not

purport to be all-inclusive or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties should

conduct their own investigation and analysis of the Company and the data set forth in this information. VOS makes no representation or warranty as to

the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information

contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of its

evaluation of the Company.

This Information includes certain statements and estimates provided by the Company with respect to the projected future performance of the

Company. Such statements, estimates and projections reflect various assumptions by management concerning possible anticipated results, which

assumptions may or may not be correct. No representations are made as to the accuracy of such statements, estimates or projections. Prospective

investors will be expected to have conducted their own due diligence investigation regarding these and all other matters pertinent to investment in the

Company.

This presentation may contain statements that are not historical facts, referred to as “forward looking statements.” The corporation’s actual future

results may differ materially from those suggested by such statements, depending on various factors including those described in filings made with the

SEC.

2

EXECUTIVE SUMMARY AND GROWTH PLATFORM

Mission

NaSCFI goal is to be the largest STEM CELL THERAPY AND BANKING services player in the world.

CONVERGENCE

The company’s technology vision is to focus on convergence of all STEM CELL THERAPY and STEM CELL BANKING in a manner that

Patient can seamlessly get treatment or services at door step. . The company intends to do that by designing products and services that

are pioneering and at least a few years ahead of its competition. The company believes that profitability and revenue growth must go hand

in hand.

With no competitors who can match the completeness of its vision or its distinct advantages, NaSCFI is ideally positioned to seize an

enormous “green field” opportunity. Continually cited for the high quality of its offering, NaSCFI has built an outstanding reputation among

a large, impressive customer base. With a strong recurring, Stem Cell therapy as a Therapeutic Cure model, NaSCFI is positioned to be a

leading player in the Healthcare, surely moving towards the disease free world

4

VOS HEALTHCARE Introduction

VOS Healthcare Pvt Ltd (the “Company”) was founded in 2011 by VOS Healthcare LLC, USA, a Washington corporation. VOS Healthcare LLC, USA is a leading provider of Adult Stem cell therapy and Regenerative medicine and Stem Cell Banking ( Cord Blood and Menstrual blood banking). VOS provides therapeutic as well as storing facilities all over the globe. Our services are ranging from collection, transportation, carrier systems, sterile environment for packaging, laboratory and centers, Banking of Stem cell along with a solutions storing for variety of period and flexibility of payment all across the globe. VOS powers multiple exchanges across the world in the field of Autologous Stem cell Production, Differentiations, Newer research Treatment and Research in Biopharma conducting in excess of $100 billion at the possible sector of business on its platformsVOS’s goal is to be the leading backend powerhouse of STEM CELL THERAPY in the world. The Company’s healthcare vision is to focus on convergence of all possible therapies in Stem cell, processes of Stem Cell Banking, Culturing and Differentiation of the stem cell, Derivation and Perpetuating in to Tissue Specific Cell, Cell cytometeric counting, Sterile chain and delivery to the patient all these in a manner such that viability and sterility is maintained and the complete complex function can seamlessly flow once the collection of Stem cell has been made.With a recurring revenue base in excess of 75% +, VOS strives to work collaboratively with clients to develop innovative technology strategies and solutions that address specific business challenges. VOS combines the newest technologies with its capabilities in distant consulting, Advance Research and Cell therapy design and integration, Franchising and business to meet the individual needs of patients and with the continuous changes occurring in the diseases grading and presentation and its treatment.The Company has its headquarters in Seattle, Washington, and has domestic operations in New Jersey, Pittsburgh. The Company also has offices in four other countries namely Australia, England, Poland and India. Through its various VOS based software platforms, VOS employs 300 professionals providing products, support and counselling to thousands of customers on six continents across 50+ countries.VOS’s focus on quality has enabled its development unit in India to be awarded Level 5 status of the University of PittsburghMedical Center’s Capability. The Company has received numerous awards and recognition from its Healthcare industry, the media, and by customers including being ranked very high in the top 100 fastest growing companies in the world

5

Summary Highlights

Industry Leadership Opportunity by Leveraging VOS’s Strong Market Presence. The U.S. Healthcare market is a highly fragmented

$360

billion industry. VOS’s innovative Adult Stem cell Therapy and its global reach, positions it as a possible leader in the worldwide Regenerative

Medicince markets

Large, Impressive Client Base for Expansion and Cross-selling. VOS’s outstanding reputation with a large customer base and community

of

healthcare professionals offers tremendous expansion and cross-reffering opportunities to accelerate an already very strong market position

One of the Most Successful Regenerative Medicine Companies in the United States in terms of its consistency of results. VOS healthcare has

achieved consistently growing financial metrics for revenues, profits, margins, etc. With a fully post-split diluted EPS of $0.41 for the Q3 of 2011 as

compared to $0.43 in the Q3 of 2010 and $1.51 for the year 2010, VOS has set a very high benchmark for itself. The full year cumulative diluted EPS

for 2010 grew by 47% as

compared to cumulative diluted EPS of $1.03 for the year 2009.

High Growth and Profitable Recurring Revenue Model. With over 75% of its revenue generated from recurring sources, derived from a 99%

plus customer retention rate, VOS has a solid revenue base to build upon affording a high degree of visibility to its growth and future revenues. With

35% revenue

growth in 2010 and net income growth of 52% on a year-over-year basis, VOS has continued to post record-setting numbers in terms of income and

EPS

Consistency of Performance over the last many years.

.

2010 2009 2008 2007 2009 2008 2007 2006

Q3 2011 Q2 2011 Q1 2011 Q4 2010

(Diluted earnings per share reflects the 3-for-1 stock split effective January 5, 2010)

6

2010 2009 2008

2010 2009 2008

Operating Margins 41% 30% 23%

Net income in thousand

$

42 9 1

Growth of 2010 over

other years

52% 116% 365%

Diluted EPS in $ 1.52 1.03 0.36

Growth of 2010 over

other years

39% 99% 278%

2010 2009 2008

Operating

Margins

41% 30% 23%

2011 Q3 Q2 Q1 Q42010

Operating Margins 42% 44% 39% 39%

Summary Highlights

7

Unique Differentiation Enhances VOS Healthcare’s Leadership OpportunityVOS Healthcare’s exchanges power transactions between hundreds of thousands of patients for these services of stem cell banking and therapy.VOS Healthcare’s services extends close to 0.15 million patients every year. VOS Healthcare’s revenue turnaround sums in excess of $0.5 million in the United States along with overseas business. In Australia the majority of VOS Healthcare work focuses on the Stem cell Therapy especially on diabetes and cancer treatment. VOS Healthcare’s on-demand Menstrual and Adipose Banking used by 100,000 plus users around the world. With the aggregation of a large community of Stem Cell banking and therapeutics , VOS Healthcare is seen as a Mentor to Stem Cell markets by these entities. Many Countries are still out of reach of VOS Healthcare Regenerative Medicine services , gives us a chance to expand and work harder to reach every corner of the globe.

VOS Healthcare has a global reach in Regenerative Medicine knowledge.VOS Healthcare powers businesses in more than 50 countries today across six continents. VOS Healthcare has a global footprint with in excess of 10+ offices today world-wide.

VOS Healthcare provides a multi-layer centers(Bud and Root collection center)and advanced lab and research labs with world-wide quick co-ordination and support, unlike any other player in the regenerative industry that addresses these markets.

VOS Healthcare systems are multi-lingual, multi-currency and work in French, Portuguese, Spanish, Japanese, Chinese and English.

With fully owned offshore facilities in India, VOS Healthcare has the ability to reduce the cost structure of acquired companies and increase their efficiency.VOS Healthcare’s centers in India have Carnegie Mellon’s highest CMMI 5 rating and that establishes the quality of VOS Healthcare’s operations to any of its prospective customers

Experienced Executive Management Team with Health Expertise and Industry Recognition.VOS Healthcare’s team includes Physicians, Physician Research, Biotechnologists, Biologist, Nurses and Other accessories Staff with a deep understanding of the Regenerative Medicine spanning an ample of years of experience amongst them. Its infrastructure andexperienced executive management team is highly capable of sustaining its leadership and developing VOS Healthcare into an even larger organization.

Global Footprint

Our markets and our clients cross geographic boundaries. VOS employs hundreds of insurance & technology professionals providing

products, support and consultancy to thousands of customers on six continents across 50+ countries through 30+ offices.

8

FINANCIAL SNAPSHOT

The Turnaround

$42.00

! In 2007 VOS Healthcare had $12 Thousand in Net Losses.

! In 2010 VOS had $42.0 Thousand of Net Income.

2010

10

$9.00

$1.00

Recurring Revenue Streams with

Consistent Growth and Profitability

! 28% revenue growth in Q3 of 2011 as compared to Q3 of 2010

! 35% annual revenue growth in 2010 as compared to 2009, 77% as compared to

2008 and 209% as compared to 2007.

! Long-term client relationships with 99.5% retention rates

! Stable, predictable base of recurring revenues

! Approximately 75% plus in recurring revenue streams

! Scaling on-demand model of 40% operating margin levels in 2010

! 52% annual net income growth in 2010 as compared to 2009, 116% as

compared to 2008, 365% as compared to 2007.

$42.84

$9.25

45%

$3.75

$24.10

Revenue Growth & Net Margins (after taxes)

11

$92.84

Recurring Revenue Streams with

Consistent Growth and Profitability

The net income at the end of 2010 grew to $ 42.3 thousand as compared to cumulative net

income of $ 9.4 Thousand at the end of 2009

*Diluted earnings per share reflects two 3-for-1stock splits, namely the 3-for-1 stock split

effective October 9, 2008 and the 3-for-1stock split effective January 5, 2010

$1.3

$0.21

$42.3

$9.4

$1.51

$88.8

$0.15

VOS Net Income Growth & Diluted EPS*

12 A

0.4 1.03

1.56

2.08

Operating Income and

Operating Cash Flow

Operating Income Quickly grew Realized through Cash Flows

$52.507Combined Operating Income from 2008-2010 = $0.1 Million

Combined Operating Cash Flows from 2008-2010 = $.4 Million

$52.779Realized Operating Cash Flow over 3 yrs. = 300%

Operating Income (in thousands)

Operating cash flows (in thousands)

$12.801

$6.712$15.039

2007

$39.256

$33.877

2008 2009 2010

13

$4.375

Operating Cash Flow

Operating Cash Flow used for:

! Support Organic Growth

! Finance Business Acquisitions

! Re-payment of Debt

! Re-purchase Shares of Common Stock

Operating cash flow (in thousands)

$15.039

$4.375

2007

$52.779

$33.877

2008 2009 2010

$51.933

YTD 2011

14

Recurring Income Streams with

Consistent Growth in Margins

Net Income (in millions)

Operating Margins

$14.00

$12.40

40% 40%

Q1-10 Q2-10

$16.70

$15.90

39% 39%

Q3-10 Q4-10

$22.30

$16.50

$15.20

44%42%

39%

Q1-11 Q2-11 Q3-11

VOS Operating Margins & Net Income Growth

15

Balance Sheet Metrics

Healthy Balance Sheet with Improving Metrics & Liquidity

Q3 2011 2010 2009 2008

Current Ratio 1.08 1.56 0.62 0.47

Cash Balance (in thousands) $13.941 $23.397 $19.227 $9.475

Working Capital (in thousands) $3.891 $21.697 $(28.582) $(28.330)

Debt/TTM EBITDA 0.35 0.52 0.96 1.53

Debt to equity ratio 0.09 0.15 0.31 0.75

16

Balance Sheet

$35.3

Debt

Dec 31, 2010 - $35.3

Sept 30, 2011 - $27.2

2011 Uses of Cash

Share buybacks - $62.7

Extinguishment of Convertible Debt - $6.8

($ in Thousands)

$27.2

As of As ofDec 31 2010 Sept 30 2011

17

INDUSTRY AND MARKET OVERVIEW

On-Demand Stem Cell Therapy

Industry & Market Overview

Retrieval centerDifferentiating Lab

Stem cell Banking

VOS’s footprint addresses

many of the most strategic requirements

of the Adult

Stem cell therapy industryDisease treatment

Global Services

Research Lab

19

Umbilical cord bankingEnrollmentCollectionProcessingPreservationMenstrual blood banking

Retrieval center Franchise centerSterile collectionsPackagingHome collections kitsBar-coded labeling Courier Centrifuging

Cell culturingCell preservations CryotherapySterilizationSegregation Storing Recombinant geneticsRestructuring DifferentiationCulturing and growing

DiabetesLiver diseasesCardiovascular disordersBone disorder CancerNeuromuscular diseasesLung diseaseErectile dysfunctionAnti-ageing & cosmetics

United states of America

United kingdom

Poland

India

Australia

Canada

United states of America

United Kingdom

Germany

Poland

Japan

India ( on going)

21

REVENUE DRIVERS & NEW GROWTH INITIATIVES

Exchanges Continue to Grow with

Recurring Revenue Streams

2%

15%

22%

Cord Blood banking

61%

Menstrual blood

Banking

4%

16%

11%

69%Adult Stem cell therapy

2010 Q3 2011

23

Franchise for

collection

Franchise for

collection

Menstrual blood

Banking

Cord Blood banking

Adult Stem cell therapy

25

What is Adult Stem cell?

26

VOS’s Revenue Drivers - Exchange

VOS ExchangeStraight Through Processing

28

Brief Biodata of Directors

DR Tapan ShahCEO, VOS Healthcare LLC, MS, DNB, FaCS, FRCS, MRCP, PhD

Prior to establishing VOS Healthcare LLC, USA, he was Vice President of ReeCell for Ebix Inc, a world leader in Bioengineering and Biopharma and biotechnology. Based in USA, he being a Liver and Pancreatic Transplant surgeon along with his dedication towards regenerative medicine, he developed a core initiation to develop a medical stream to bring disease free world and a cure to all the diseases.

Dr.Tapan Shah was also an account director for ten years with two global healthcare business Worldwide, where he directed many successful transplant and regenerative programs.

Dr.Tapan Shah is dedicated to sharing his experience with the international audience. He regularly accepts invitation to chair and speak in top-notched events across Asia and Europe. Recently, he was appointed chairman of REGER MED2009. He contributes leadership opinion articles on ORGAN TRANSPLANTATION AND REGENERATIVE MEDICINE issues to international publications.

He is Visiting Professor in Liver Transplantation and Stem cell Center at the UNIVERSITY OF DRESDEN, GERMANY.

Dr.Tapan Shah is founder and CEO of VOS Healthcare LLC, USA, the leading Regenerative Medicine & Stem Cell Industry on STEM CELL Therapy with a view to provide the services across Asia Pacific and Europe.

He brings more than 15 years of experience from the Healthcare industry, and has served in various positions, focusing especially on global marketing and branding strategy; brand/ product advertising; and corporate communications

Ms. Shah is responsible for expanding VOS' leadership position in the industry and provides strategic direction and business development expertise. With a prestigious list of more than 100000 customers and with products deployed all over the globe extending from North America to Australia, VOS prides itself in understanding and addressing ongoing challenges for its customers by staying ahead of the technology curve.

She has more than 10 years of Hospital Administration related experience, including strategic business development, marketing, and product management, bioengineering and patient care and counseling along with sales for domestic and international markets. Ms. Shah earned lots of patents during her tenure at Cisco (formerly known as Scientific Atlanta).

She holds a Masters of Commerce degree from The M.S University of Vadodara, Gujarat, India and a Master of Business Administration Specialization in Hospital Administration from M. S University.

Sudha shahPresident and CEO, VOS Healthcare Pvt Ltd

Sudha shah is the founding partner, Chief Executive Officer of VOS Healthcare LLC. VOS provides REGENERATIVE MEDICINE & STEM CELL BANKING and it’s the only provider for INTERNATIONALLY ACCEPTED stem cell treatment and Banking not only CORD BLOOD but also Menstrual blood, Adipose Tissues. VOS’ team of architects and application experts continue to solve complex infrastructure challenges, helping customers navigate through the convergence of services, treatment, banking and counseling.

Born on March 7, 1976, N.R. Suresh Nair is a B.E. Electrical from University of Vallabh Vidhyanagar and M B A from M.S. University (1969). Suresh Nair began his career with TCS in Mumbai and later went to Seattle, WA. Later with his vision for future developed his own company SURAN LLC, USA in Seattle WA. In 2007, Suresh Nair founded VOS HEALTHCARE LLC with two other professionals. In 2010, VOS HEALTHCARE LLC opened many international office in Poland, UK, India, Australia.

Along with the growth of VOS Healthcare LLC, USA, Suresh Nair too has grown in stature. He has received many honours and awards.

Suresh Nair ProfileBorn: March 7, 1976

Achievement: One of the founders of VOS HEALTHCARE LLC, USA;

Suresh Nair is the Non-Executive Chairman and Chief Mentor of VOS HEALTHCARE LLC. He is an epitome of the fact that honesty, transparency, and moral integrity are not at variance with business acumen. He set new standards in corporate governance and morality.

New Growth Initiatives

Phase I

Developing Root

Labs

Phase II

Developing bud

centers (

franchise)

Phase III

Developing Full

fledged Lab

Phase IV

Developing

Research Lab

New Growth Initiatives

Differentiation Labs

INTERFACED

Patient Care Executive

On-Demand

Stem Cell

TherapyINTERFACED INTERFACED

INTERFACED

Associated research lab

FranchiseBud collectionRoot collection

! Used by BUD Collection center , ROOT Collection center, Review and Ethical Committee, Differentiating Lab, Research LabPatient care Executive, Physicians and Social workers, courier, Stem cell Banks

31

GROWTH AND FUTURE EXPANSION POTENTIONAL

•Among U.S. residents ages 65 years and older, 10.9 million, or 26.9 percent, had diabetes in 2010.•About 215,000 people younger than 20 years had diabetes—type 1 or type 2—in the United States in 2010.•About 1.9 million people ages 20 years or older were newly diagnosed with diabetes in 2010 in the United States.•In 2005–2008, based on fasting glucose or hemoglobin A1C (A1C) levels, 35 percent of U.S. adults ages 20 years or older had pre-diabetes—50 percent of adults ages 65 years or older. •U.S. population in 2010 yields an estimated 79 million American adults ages 20 years or older with pre-diabetes.•Diabetes is the leading cause of kidney failure, nontraumatic lower-limb amputations, and new cases of blindness among adults in the United States.•Diabetes is a major cause of heart disease and stroke.•Diabetes is the seventh leading cause of death in the United States.

Adult Stem Cell Therapy- DiabetesDiabetes affects 25.8 million people of all ages8.3 percent of the U.S. population

•The prevalence of ALD is estimated at >8.4 million people.•Liver Diseases is the foremost health risk in developing countries and ranks third in developed countries.•Liver Diseases caused by ALD, Hepatitis C & B, Other causes•Only treatment for liver diseases were LIVER TRANSPLANTATION•Liver Transplantation is not only very cost but available at very few centers•Liver Transplantation is not always possible due to non availability of organ

Adult Stem Cell Therapy- Liver Disease

• 33.5 percent of adults 20 years and older in America have high blood pressure; 80 percent are aware of their condition but less than half have their condition under control.•23.1 percent of men and 18.1 percent of women are cigarette smokers; 19.5 percent of students in grades 9 through 12 report current tobacco use.•15 percent of adults 20 and older have total serum cholesterol levels of 240 mg/dL or higher.•8 percent of adults have been diagnosed with diabetes mellitus; 36.8 percent have prediabetes.•More than 67 percent of adults are overweight.•During the past 30 years, the prevalence of obesity in children 6 to 11 years has increased from about 4 percent to more than 20 percent

Adult Stem Cell Therapy-Heart Disease

•Cancer rates could further increase by 50% to 15 million new cases in the year 2020•malignant tumours were responsible for 12 per cent of the nearly 56 million deaths worldwide•The World Cancer Report tells us that cancer rates are set to increase at an alarming rate globally• from 10 million new cases globally in 2000, to 15 million in 2020•About 60 per cent of cases occur in developing countries, with the highest incidence rates coming in Eastern Asia

Adult Stem Cell Therapy-Cancer

Adult Stem Cell Therapy- Neurology•Currently 30 million people with dementia in the world•13.9% of people aged 71+ are affected by dementia•Nearly half of people aged 85 and older (43 percent) have Alzheimer’s Disease•An estimated 5.4 million people have Alzheimer’s disease in USA•4.6 million new cases annually ( one new case very 7 second)•Over 100 million people would be affected by 2050•14.9 million unpaid caregiver•183 billion dollars in annual costs•1 in 8 older Americans have ALZHEIMER DISEASE

Prevalence of Parkinson's Disease: 21 million peoplePrevalence Rate: approx 1 in 272 or 0.37% or 1 million peopleUndiagnosed prevalence of Parkinson's Disease: estimated 3-4 million peopleUndiagnosed prevalence rate: approx 1 in 90 or 1.10% or 3 million peopleDeath rate extrapolations for Parkinson's Disease: 14,593 per year, 1,216 per month, 280 per week, 39 per day, 1 per hour

Adult Stem Cell Therapy- Ortho/ Knee

•13.9% of adults aged 25 + and 33.6% (12.4 million) of those 65+ has OsteoArthritis•An estimated 41.9 million US adults in 2011 has OA•Incidence rates increased with age, and level off around age 80.•Women had higher rates than men, especially after age 50 •$25.9 billion estimated costs of knee and hip replacements in 2011•Average direct costs of OA ~$9,600 per year out-of-pocket expenses.•OA of the knee is 1 of 5 leading causes of disability among non-institutionalized adults•80% of patients with OA have some degree of movement limitation •25% cannot perform major activities of daily living (ADL’s)• About 40% of adults with knee OA reported their health “poor”

Population

• 7 billion

• 1 billion Indians

Diseases

• 1 out of 6 has lethal diseases

• 1 out of 3 has morbid or lethal diseases

Stem cell therapy

• 1 out of 3 needs stem cell therapy

• If cosmetic/anti-aging included all needs stem cell therapy

7 billion customers needs us

New Growth Initiatives - Exchange

FRANCHISE : BUD collection centers

VOS HEALTHCARE ( NaSCFI) Labs is introducing a program by which satellite labs are built in foreign sites. VOS HEALTHCARE ( NaSCFI) has been producing two types of stem cells from discarded human umbilical cords(cord blood) AND Adult Stem cells ( adipose, menstrual, neural). These cells have proven, in international as well as our own experience, to be quite effective and safe in a number of different health conditions. VOS HEALTHCARE ( NaSCFI) also realizes that having laboratories in individual states and countries would increase their availability, help more people, avoid the problems of transportation and importation of such sensitive live cells. In particular, keeping the cells within the bounds of one state removes jurisdiction from Federal agencies, such as the Food and Drug Administration and the Federal Trade Commission.

Some desire to establish a stem cell treatment center, as well as the production lab. One lab could supply many treatment centers. Our intention is to provide labs in individual states, on a first-come, first-served basis, so that there will not be excessive competition for the existing market. We will continue a system-wide marketing program, which will provide demand for the product.

Research-level labs will also be available, for an additional cost. These may also be financed by the same organization. We will have one research lab for each ten production labs. Production labs would partially support the research labs, and intellectual property would be shared throughout the system.

The above price does not include: full research lab capabilities, vehicles, income or other taxes, back-up power, or real estate, but does include several months rent or real-estate payments. Real-estate can also be financed.

Franchisee obligations include assistance with hiring, licensing, coordination with local medical personnel, including at least one licensed physician to order supplies, procuring a contract for cords, and local marketing. Franchisee will also provide a 10% licensing fee for each stem cell unit sold. Lab is designed to fit in a 700 ft2 office or lab space

Projected profits operating at a low level (2 cords per day) would yield over $1 million yearly, and expansion up to 8 cords per day ($5 M per year) could be done with this lab.

32

New Growth Initiatives

Stem Cell Banking

Stem cell Banking

Cord blood banking Other Stem cell banking

34

•A Menstrual blood stem cell •first of its kind in India with international standard•normally discarded as unsanitary waste, is now a boon •properties and characteristics similar to both bone marrow and embryonic stem cells.•easily collected with painless and non-invasive procedures •processed and harvested at affordable rates.

Adipose stem cell banking•Adipose (fat) tissue is found throughout body. •ability to differentiate into bone, muscle, fat, nerve, and cartilage. •obtain through a simple and localized liposuction process•Adipose-derived stem cells are easy to obtain thro liposuction•same morphology, immune phenotype and differentiation capacity•free of ethical debate /abundant and easy to access.•yield more than 200 million stem cells of which 95% are mesenchymal stem cells. •cryopreservation: for almost 25 years

Fixed deposit of health

Premium of life insurance

Pension your Health Guard

•cGTP & c GMP accredited labs

•Precious gift given to every new born

•Cord and placental banking possible

•Collections network all across gynec hospitals

•Highest sterility techniques ( rated best)

•Easily collected and handled

•Helps treating many early age diseases

•Higher viable stem cell

•Banking near airport, so quick response

VOS’s Revenue Drivers - Exchange

Advance labs and Regenerative Medicine

Advance labs and Research labs

2010 - 12% Q3 2011 - 8%

Percentage of Total Revenue

35

•Advance lab

•Culturing

•Sterilization

•Cell counting

•Stimulation

•Cyro preservation

•Differentiation and growth

•Newer source of stem cell

•Newer means of delivering

•Local patches and oral delivery

•Biopharma

•More viability and efficacy

VOS’s Revenue Drivers

The healthcare Channel

•Self manageable kits•Adequate education •Door step collection and counselling•Online consultation•No OPD policy•Mass awareness activity•24*7 helpline •Ethical committee•Review committee•Finance availability•Special package for corporate groups

Patients Center

Lab

2010 - 10% Q3 2011 - 11%

Percentage of Total Revenue

37

•Coordination with patients and bud centers

•Cohesively work with root centers

•Patient counseling

•Marketing and media conferencing

•Corporate liaisioning

•Packaging and Culturing

•Achieves handling

•Labeling and forwarding

BUD collection center

Root collection center

Advance lab

Research lab

Acquisitions

!Marketplace remains robust

!Constantly evaluating companies

!Prices coming down

Criteria

!Accretive to earnings in 90-180 days

!Adds to our Customer base

!Adds to our Product base

!70% or more of recurring revenue

!Service On-Demand a must

!Low customer attrition rates

!Complements our existing product base

38

Understanding of Competitive Edge

The Secret Mantra

Cost Price Selling Price

Key Company Goals: Operating Margins of 40% or moreOn Demand Banking and Franchise generating revenue streams

39

Summary

! First mover advantage in our markets

! Large untapped market potential

! Minimal customer attrition

!75% plus recurring revenues

! Sustainable 40% operating margins

! Strong free cash flow generation

! Minimal debt

! Chairman owns 20% of the company

40

THANK YOU